CD274 and neoplasm: A study by Rimm et al. in triple‐negative breast cancer (TNBC) treated with a combination of immunotherapy (durvalumab) and chemotherapy (the Impassion 130 and the Keynote 522 trials) examined PD‐L1 expression on both tumor and immune cells.26